Theralase Technologies Inc. (TLT : TSX-V)
Common Stock
$0.24
CAD
+0.01 (2.13%)
Last updated: 2026-06-29
TLT
Theralase Technologies Inc.
WealthAwesomePerformance
1 Day
+2.13%
1 Week
+2.13%
1 Month
+6.67%
YTD
+33.33%
Key Statistics
Market Cap
$69.48M
52W High
$0.41
52W Low
$0.15
P/E Ratio
-
50 Day MA
$0.26
200 Day MA
$0.24
Beta
0.60
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 6/29/2026 | $0.23 | $0.24 | $0.23 | $0.24 | $0.24 | 161,653 |
| 6/26/2026 | $0.23 | $0.23 | $0.23 | $0.23 | $0.23 | 68,310 |
| 6/25/2026 | $0.23 | $0.23 | $0.23 | $0.23 | $0.23 | 3,587 |
| 6/24/2026 | $0.24 | $0.24 | $0.23 | $0.23 | $0.23 | 118,819 |
| 6/23/2026 | $0.23 | $0.23 | $0.23 | $0.23 | $0.23 | 41,517 |
| 6/22/2026 | $0.24 | $0.24 | $0.23 | $0.23 | $0.23 | 37,722 |
| 6/19/2026 | $0.23 | $0.23 | $0.23 | $0.23 | $0.23 | 1,202 |
| 6/18/2026 | $0.24 | $0.24 | $0.23 | $0.23 | $0.23 | 182,484 |
| 6/17/2026 | $0.24 | $0.24 | $0.24 | $0.24 | $0.24 | 16,948 |
| 6/16/2026 | $0.24 | $0.24 | $0.23 | $0.24 | $0.24 | 90,302 |
Analyst Price Targets
Based on analyst covering TLT
Wall Street analysts forecast TLT stock price to rise 191.7% over the next 12 months.
Consensus
No RatingAvg. Target
C$0.70
+191.7% Upside
Current Price
C$0.24
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TLT's historical volatility
30-Day Vol
49.8%
Annualized
90-Day Vol
95.3%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.20
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$0.23 | C$0.19 โ C$0.27 |
| 60 trading days | C$0.21 | C$0.17 โ C$0.27 |
| 90 trading days | C$0.20 | C$0.15 โ C$0.27 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Theralase Technologies Inc.
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. The company operates in two segments, Drug Division and Device Division. It engages in the research and development of Rutherrin, an injectable form of Ruvidar for the treatment of glio blastoma multiforme, a form of brain cancer, non-small cell lung cancer, pancreatic cancer, colorectal cancer, and muscle invasive bladder cancer; and Ruvidar, a topical treatment for herpes simplex virus-1 lesions and an extracorporeal treatment for lymphoma, leukemia, and multiple myeloma. The company also researches, develops, manufactures, and distributes Cool Laser Therapy systems to healthcare practitioners for the healing of pain. Theralase Technologies Inc. is based in Toronto, Canada.
Financials
- Revenue (TTM)
- $857,912
- EBITDA
- $-3.55M
- Profit Margin
- 0.00%
- ROE (TTM)
- -242.19%
- EPS (Diluted)
- -0.01
- Book Value
- 0.01
Classification
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Group
- Health Care Equipment & Services
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About TLT
Articles Featuring TLT.V
Latest articles and analysis covering TLT.V
